In the Pipeline: Treating HIV With a Patch Instead of Pills
October 28, 2011
Preliminary research suggests that HIV drugs could be delivered via a transdermal patch. The developers, led by Anthony Ham, director of formulations at the pharmaceutical research company ImQuest BioSciences, presented a study at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, which was held in Washington, D.C., from Oct. 23 through 27.
Ham and his colleagues tested the effectiveness of administering IQP-0410, an HIV drug that is currently under development, via a skin patch. They found that the patch delivered more than 96 percent of the drug over a week-long period. While the method has yet to be tested in animals and humans, this is promising news, especially for those with adherence difficulties.
Moreover, compared to pills and needles, the low-cost patch could be more affordable and accessible, which could thereby drive down the ever-growing cost of current HIV treatment -- perhaps even impacting our ADAP crisis. Only time will tell.
Warren Tong is the research editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
Copyright © 2011 The HealthCentral Network, Inc. All rights reserved.
This article was provided by TheBody.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.